Stockreport

Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF - Data to be presented at 21st International Congress of Parkinson’s Disease and Movement Disorders, June 5-8, 2017 - - Revance to host conferenc [Read more]